We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
Although semiconductors and other AI-related stocks continue to lift the broader market, investors may want to turn their attention to the medical sector.
Not to say it’s time to shift away from tech-heavy portfolios, but the essentiality of healthcare products and services may be desirable if energy prices remain elevated due to production disruptions in the Middle East.
On top of this, many medical stocks are making the case for undervaluation, and here are three that recently made their way onto the coveted Zacks Rank #1 (Strong Buy) list with appealing growth trajectories as well.
DaVita – DVA
Stock Price: $197
As a top-performing medical stock, DaVita (DVA - Free Report) ) shares have spiked over 70% year to date as a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure.
DaVita’s increased probability continues to attract investors with 40% EPS growth expected this year, and fiscal 2027 earnings are projected to pop another 22% to $18.37 per share.
Despite the impressive YTD rally, DaVita stock is still trading at 13X forward earnings, offering a pleasant discount to its Zacks Medical-Outpatient and Home Healthcare Industry average of 17X and the benchmark S&P 500’s 23X.
Image Source: Zacks Investment Research
Globus Medical – GMED
Stock Price: $77
Standing out as a strong buy-the-dip candidate is Globus Medical Inc. (MED - Free Report) ), a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders.
A key part of Globus Medical’s investment appeal is its broad and differentiated portfolio, with more than 200 products and technologies designed to treat a wide range of musculoskeletal conditions across the spine, extremities, and pelvis.
Globus Medical has sales operations in over 65 countries worldwide, and after dipping over 10% in 2026, its stock looks more appealing at a 16X forward earnings multiple. This offers a nice discount to its Zacks Medical-Instruments Industry average of 22X, with Globus Medical’s EPS expected to spike 17% this year and projected to increase another 8% in FY27 to $5.05.
Image Source: Zacks Investment Research
Progyny – PGNY
Stock Price: $22
Like Globus Medical, Progyny (PGNY - Free Report) ) stock is making a strong argument as one of the more appealing buy-the-dip targets to consider at the moment.
Progyny offers exposure to the expanding fertility solutions market, which has been accelerating due to rising infertility rates and broader cultural acceptance of fertility treatments, including growing employer adoption of fertility coverage, along with increased investment in fertility care infrastructure.
Magnifying its affordable price tag of just over $20 a share, Progyny stock is trading at a very reasonable 12X forward earnings multiple, with its Zacks Medical Services Industry average at 15X. Progyny’s EPS is expected to remain unchanged at $1.89 in FY26, but FY27 earnings are projected to increase 11% to $2.11 per share.
Image Source: Grand View Research
Bottom Line
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular-growth profiles could become even more attractive if an economic downturn does emerge from elevated energy prices amid geopolitical tensions in the Middle East.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
3 Highly Ranked Medical Stocks to Buy Now: DVA, GMED, PGNY
Although semiconductors and other AI-related stocks continue to lift the broader market, investors may want to turn their attention to the medical sector.
Not to say it’s time to shift away from tech-heavy portfolios, but the essentiality of healthcare products and services may be desirable if energy prices remain elevated due to production disruptions in the Middle East.
On top of this, many medical stocks are making the case for undervaluation, and here are three that recently made their way onto the coveted Zacks Rank #1 (Strong Buy) list with appealing growth trajectories as well.
DaVita – DVA
Stock Price: $197
As a top-performing medical stock, DaVita (DVA - Free Report) ) shares have spiked over 70% year to date as a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure.
DaVita’s increased probability continues to attract investors with 40% EPS growth expected this year, and fiscal 2027 earnings are projected to pop another 22% to $18.37 per share.
Despite the impressive YTD rally, DaVita stock is still trading at 13X forward earnings, offering a pleasant discount to its Zacks Medical-Outpatient and Home Healthcare Industry average of 17X and the benchmark S&P 500’s 23X.
Image Source: Zacks Investment Research
Globus Medical – GMED
Stock Price: $77
Standing out as a strong buy-the-dip candidate is Globus Medical Inc. (MED - Free Report) ), a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders.
A key part of Globus Medical’s investment appeal is its broad and differentiated portfolio, with more than 200 products and technologies designed to treat a wide range of musculoskeletal conditions across the spine, extremities, and pelvis.
Globus Medical has sales operations in over 65 countries worldwide, and after dipping over 10% in 2026, its stock looks more appealing at a 16X forward earnings multiple. This offers a nice discount to its Zacks Medical-Instruments Industry average of 22X, with Globus Medical’s EPS expected to spike 17% this year and projected to increase another 8% in FY27 to $5.05.
Image Source: Zacks Investment Research
Progyny – PGNY
Stock Price: $22
Like Globus Medical, Progyny (PGNY - Free Report) ) stock is making a strong argument as one of the more appealing buy-the-dip targets to consider at the moment.
Progyny offers exposure to the expanding fertility solutions market, which has been accelerating due to rising infertility rates and broader cultural acceptance of fertility treatments, including growing employer adoption of fertility coverage, along with increased investment in fertility care infrastructure.
Magnifying its affordable price tag of just over $20 a share, Progyny stock is trading at a very reasonable 12X forward earnings multiple, with its Zacks Medical Services Industry average at 15X. Progyny’s EPS is expected to remain unchanged at $1.89 in FY26, but FY27 earnings are projected to increase 11% to $2.11 per share.
Image Source: Grand View Research
Bottom Line
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular-growth profiles could become even more attractive if an economic downturn does emerge from elevated energy prices amid geopolitical tensions in the Middle East.